ArticleBMC endocrine disorders2025
Metabolic syndrome among people living with HIV on first-line antiretroviral therapy in scarce-resource settings: an evidence from Tanzanian facility-based survey.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic syndrome (MetS) is becoming prevalent among People living with HIV (PLWHIV), attributed to antiretroviral therapy, HIV infection and other concomitant factors. A high burden of HIV/AIDs and Non-communicable diseases in Sub-Saharan Africa calls for an extra focus on the MetS among people living with HIV. The study aimed at assessing the factors associated with MetS among PLWHIV on the first-line antiretroviral therapy.
methodsThis was a cross-sectional design whereby a convenience sampling technique was used to recruit a sample of 255 participants. The interview-guided questionnaire was used to obtain relevant information from the study participants as well as to record physical measurements (Blood pressure, weight, height and body mass index) and biochemical profiles (fasting blood glucose, lipid profile, CD4 count, and Hemoglobin level). MetS was established by using the Adult Treatment Panel III criteria. Descriptive statistics and binary logistic regression were used to analyze the data, and all statistical analyses were performed using Stata version 17.0. A P value less than 0.05 was considered for statistical significance.
resultsThe mean age and BMI were 46 ± 2 years and 25.0 ± 5.3 kg/m
conclusionThe prevalence of MetS in this study was relatively high among PLWHIV on first-line ART. Age above 45 years, being single, current smoking, and obesity were independent predictors of MetS. Regular monitoring for clinical and laboratory parameters, surveillance of drug effects and behavioral interventions are needed to optimize the management and prevention of metabolic disorders in PLWHIV. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.